Selecting a Treatment Regimen
Figure 2. Managing and Treating Patients with Chronic HCV Infection, Genotype 2 or 3
Eligible Patient Anti-HCV Positive
Determine quantitative HCV RNA Determine HCV genotype
If genotype 2 or 3 Liver biopsy optional
Treat with PegIFN plus RBV, 800 mg for 24 weeks
Qualitative HCV RNA at 24 weeks to establish end of treatment response
HCV RNA detected
HCV RNA not detected
Treatment failed
Qualitative HCV RNA at week 48 (24 weeks aſter ending treatment) to establish SVR
8
